Subjects:
BloodWork, Free Research Articles, Immunobiology and Immunotherapy, Lymphoid Neoplasia
Topics:
abdomen, apoptosis, atypical, biopsy, blast cells, bone marrow, bone marrow biopsy, cd19 antigens, cell death, chimeric antigen receptors
A 5-year-old girl with relapsed/refractory B lymphoblastic leukemia was treated with T cells expressing a chimeric antigen receptor (CART) targeting CD19. Preinfusion, the bone marrow was 90% involved and a computed tomography scan demonstrated extensive thoracic/abdominal/pelvic lymphadenopathy. The patient developed cytokine release syndrome (CRS) 3 days after infusion. Eight days after infusion, a soft-tissue mass involving the right eyelid and periorbital region developed. Although CRS resolved by day 11, this mass increased in size until day 18, when a biopsy was performed to determine the etiology. / Hematoxylin and eosin–stained sections (panel A; original magnification ×100) show sheets of large atypical blasts (bounded by yellow line) surrounded by a lymphohistiocytic infiltrate. Apoptosis and debris is noted at the tumor–T-cell interface (panel B, arrow; original magnification ×400) consistent with cell death. CD19 immunostain (panel C, brown; original magnification ×100) highlights B lymphoblasts, whereas CD8 immunostain (panel D, brown; original magnification ×100) highlights surrounding T cells. The mass regressed shortly after biopsy without further intervention. A subsequent bone marrow biopsy demonstrated morphologic remission. These findings are consistent with delayed but active tumor cell killing by CART cells.
View largeDownload PPT

A 5-year-old girl with relapsed/refractory B lymphoblastic leukemia was treated with T cells expressing a chimeric antigen receptor (CART) targeting CD19. Preinfusion, the bone marrow was 90% involved and a computed tomography scan demonstrated extensive thoracic/abdominal/pelvic lymphadenopathy. The patient developed cytokine release syndrome (CRS) 3 days after infusion. Eight days after infusion, a soft-tissue mass involving the right eyelid and periorbital region developed. Although CRS resolved by day 11, this mass increased in size until day 18, when a biopsy was performed to determine the etiology.

Hematoxylin and eosin–stained sections (panel A; original magnification ×100) show sheets of large atypical blasts (bounded by yellow line) surrounded by a lymphohistiocytic infiltrate. Apoptosis and debris is noted at the tumor–T-cell interface (panel B, arrow; original magnification ×400) consistent with cell death. CD19 immunostain (panel C, brown; original magnification ×100) highlights B lymphoblasts, whereas CD8 immunostain (panel D, brown; original magnification ×100) highlights surrounding T cells. The mass regressed shortly after biopsy without further intervention. A subsequent bone marrow biopsy demonstrated morphologic remission. These findings are consistent with delayed but active tumor cell killing by CART cells.

A 5-year-old girl with relapsed/refractory B lymphoblastic leukemia was treated with T cells expressing a chimeric antigen receptor (CART) targeting CD19. Preinfusion, the bone marrow was 90% involved and a computed tomography scan demonstrated extensive thoracic/abdominal/pelvic lymphadenopathy. The patient developed cytokine release syndrome (CRS) 3 days after infusion. Eight days after infusion, a soft-tissue mass involving the right eyelid and periorbital region developed. Although CRS resolved by day 11, this mass increased in size until day 18, when a biopsy was performed to determine the etiology. / Hematoxylin and eosin–stained sections (panel A; original magnification ×100) show sheets of large atypical blasts (bounded by yellow line) surrounded by a lymphohistiocytic infiltrate. Apoptosis and debris is noted at the tumor–T-cell interface (panel B, arrow; original magnification ×400) consistent with cell death. CD19 immunostain (panel C, brown; original magnification ×100) highlights B lymphoblasts, whereas CD8 immunostain (panel D, brown; original magnification ×100) highlights surrounding T cells. The mass regressed shortly after biopsy without further intervention. A subsequent bone marrow biopsy demonstrated morphologic remission. These findings are consistent with delayed but active tumor cell killing by CART cells.
View largeDownload PPT

A 5-year-old girl with relapsed/refractory B lymphoblastic leukemia was treated with T cells expressing a chimeric antigen receptor (CART) targeting CD19. Preinfusion, the bone marrow was 90% involved and a computed tomography scan demonstrated extensive thoracic/abdominal/pelvic lymphadenopathy. The patient developed cytokine release syndrome (CRS) 3 days after infusion. Eight days after infusion, a soft-tissue mass involving the right eyelid and periorbital region developed. Although CRS resolved by day 11, this mass increased in size until day 18, when a biopsy was performed to determine the etiology.

Hematoxylin and eosin–stained sections (panel A; original magnification ×100) show sheets of large atypical blasts (bounded by yellow line) surrounded by a lymphohistiocytic infiltrate. Apoptosis and debris is noted at the tumor–T-cell interface (panel B, arrow; original magnification ×400) consistent with cell death. CD19 immunostain (panel C, brown; original magnification ×100) highlights B lymphoblasts, whereas CD8 immunostain (panel D, brown; original magnification ×100) highlights surrounding T cells. The mass regressed shortly after biopsy without further intervention. A subsequent bone marrow biopsy demonstrated morphologic remission. These findings are consistent with delayed but active tumor cell killing by CART cells.

Close modal

For additional images, visit the ASH IMAGE BANK, a reference and teaching tool that is continually updated with new atlas and case study images. For more information visit http://imagebank.hematology.org.

© 2017 by The American Society of Hematology
2017
Sign in via your Institution